Immunocompromised Children with Severe Adenoviral Respiratory Infection
Table 4
Matched case control analysis of immunocompromised cases with severe adenoviral respiratory infection and immunocompetent controls with severe adenoviral respiratory infection.
Characteristic
Immunocompromised cases ()
Immunocompetent controls ()
value
Age (years)
3.9 (IQR 2.6–12.7)
3.6 (IQR 1–8.5)
0.11
Female sex
11 (58%)
12 (63%)
0.74
PIM3 predicted mortality (percent)
5.3 (IQR 1.1–5.6)
3.3 (IQR 1.1–4.6)
0.13
Hospital LOS (days)
45 (IQR 17–112)
13 (IQR 4–34)
0.06
ICU LOS (days)
20 (IQR 7–48)
6 (IQR 3–23)
0.07
Respiratory failure
17 (89%)
14 (74%)
0.45
ALC (cells/mm3)
560 (IQR 50–1520)
2490 (IQR 1840–4070)
0.004
Bacterial coinfection
3 (5%)
2 (11%)
1.00
Viral coinfection
7 (37%)
4 (21%)
0.45
MODS
11 (58%)
2 (11%)
0.01
ARDS
7 (37%)
2 (11%)
1.00
RRT
7 (37%)
0
0.02
ECLS
1 (5%)
0
1.00
Case fatality
11 (58%)
1 (5%)
0.004
Values expressed as (%). Continuous variables are shown as median (interquartile range). PIM3: Paediatric Index of Mortality 3; ICU: intensive care unit; LOS: length of stay; ALC: absolute lymphocyte count; MODS: multiple organ dysfunction syndrome; ARDS: acute respiratory distress syndrome; RRT: renal replacement therapy; ECLS: extracorporeal life support.
